Successful Response to First-Line Carboplatin, Pemetrexed, and Bevacizumab for Peritoneal Mesothelioma: Two Case Reports.

ABSTRACT:

Introduction

Peritoneal mesothelioma is an extremely rare malignancy of the peritoneum. It has a poor prognosis, and the optimal systemic chemotherapy remains controversial. Here, we report two cases of peritoneal mesothelioma with long-term survival and complete response to carboplatin, pemetrexed, and bevacizumab chemotherapy.

Case presentation

Both patients were treated with six cycles of carboplatin (AUC 5), pemetrexed (750 mg/m²), and bevacizumab (15 mg/kg) followed by pemetrexed and bevacizumab as maintenance therapy. Partial response continued for over 6 years in case 1, and complete response was obtained in case 2. The patient in case 1 died after 7 years due to accidental pneumonia, and the patient in case 2 remained disease-free for over 2 years after in

SUBMITTER: Koizumi T 

PROVIDER: S-EPMC11857156 | biostudies-literature | 2025 Jan-Dec

REPOSITORIES: biostudies-literature